Topics

FDA grants Johnson & Johnson’s Invokana new kidney disease approval

05:21 EDT 2 Oct 2019 | Pharmafile

Johnson & Johnson’s Invokana (canaglifolozin) has become the only drug in the SGLT2 inhibitor class to be approved by the FDA for treating diabetic kidney disease (DKD) and to reduce the risk of hospitalisation for heart failure in patients with type 2 diabetes and DKD.

read more

Original Article: FDA grants Johnson & Johnson’s Invokana new kidney disease approval

NEXT ARTICLE

More From BioPortfolio on "FDA grants Johnson & Johnson’s Invokana new kidney disease approval"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...